Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for Hard-to-Treat myeloma

NCT ID NCT02718833

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times

Summary

This study tests a combination of four drugs—elotuzumab, pomalidomide, bortezomib, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see how many patients achieve at least a partial response and to monitor side effects. The study involves 52 adults who have already tried at least two other therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Mass General/North Shore Cancer Center

    Danvers, Massachusetts, 01923, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Newton-Wellesley Hospital

    Newton, Massachusetts, 02462, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Rochester

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.